CL2022000016A1 - Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo - Google Patents
Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismoInfo
- Publication number
- CL2022000016A1 CL2022000016A1 CL2022000016A CL2022000016A CL2022000016A1 CL 2022000016 A1 CL2022000016 A1 CL 2022000016A1 CL 2022000016 A CL2022000016 A CL 2022000016A CL 2022000016 A CL2022000016 A CL 2022000016A CL 2022000016 A1 CL2022000016 A1 CL 2022000016A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- activation protein
- protein ligand
- fibroblast activation
- xaa1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7 Yc (I) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19000325.1A EP3763726A1 (en) | 2019-07-08 | 2019-07-08 | Compounds comprising a fibroblast activation protein ligand and use thereof |
EP19198810 | 2019-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000016A1 true CL2022000016A1 (es) | 2022-08-19 |
Family
ID=71409440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000016A CL2022000016A1 (es) | 2019-07-08 | 2022-01-04 | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220315554A1 (es) |
EP (1) | EP3997104A1 (es) |
JP (1) | JP2022541752A (es) |
KR (1) | KR20220032078A (es) |
CN (1) | CN114341158A (es) |
AU (1) | AU2020309161A1 (es) |
BR (1) | BR112022000144A2 (es) |
CA (1) | CA3145872A1 (es) |
CL (1) | CL2022000016A1 (es) |
IL (1) | IL289673A (es) |
MX (1) | MX2022000251A (es) |
WO (1) | WO2021005131A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
WO2023111350A2 (en) * | 2021-12-17 | 2023-06-22 | 3B Pharmaceuticals Gmbh | Carbonic anhydrase ix ligands |
WO2023152671A1 (en) | 2022-02-09 | 2023-08-17 | Novartis Ag | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
CN1163594C (zh) | 1997-09-29 | 2004-08-25 | 尖端医疗有限公司 | 体外造血细胞的刺激 |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
AU2001256325A1 (en) | 2000-03-17 | 2001-09-24 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
EP1452868A2 (en) * | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
US7399869B2 (en) | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
US20100105753A1 (en) | 2007-03-20 | 2010-04-29 | Trustees Of Tufts College | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof |
EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
JP2012503670A (ja) | 2008-09-25 | 2012-02-09 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 選択的セプラーゼ阻害剤 |
EP2483316A1 (en) | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
US9011847B2 (en) | 2010-08-13 | 2015-04-21 | Roche Glycart, AG | Anti-FAP antibodies and methods of use |
US9346814B2 (en) | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
SI2827883T1 (sl) * | 2012-03-21 | 2019-08-30 | Baxalta GmbH | Inhibitorji TFPI in postopki uporabe |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
RU2743781C2 (ru) * | 2014-06-10 | 2021-02-25 | 3Б Фармасьютикалз Гмбх | Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение |
WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
WO2017127007A1 (en) * | 2016-01-20 | 2017-07-27 | Poypeptide Laboratories Holding (Ppl) Ab | METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER |
CN109689115A (zh) | 2016-06-10 | 2019-04-26 | 拜耳制药股份公司 | 放射性药物配合物 |
CN105949282B (zh) * | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v2及其应用 |
CN106046121B (zh) * | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v1及其应用 |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
CN116617420A (zh) | 2017-10-23 | 2023-08-22 | 约翰霍普金斯大学 | 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途 |
-
2020
- 2020-07-08 WO PCT/EP2020/069308 patent/WO2021005131A1/en unknown
- 2020-07-08 CA CA3145872A patent/CA3145872A1/en active Pending
- 2020-07-08 EP EP20735648.6A patent/EP3997104A1/en active Pending
- 2020-07-08 CN CN202080062641.3A patent/CN114341158A/zh active Pending
- 2020-07-08 JP JP2022501191A patent/JP2022541752A/ja active Pending
- 2020-07-08 AU AU2020309161A patent/AU2020309161A1/en active Pending
- 2020-07-08 US US17/625,246 patent/US20220315554A1/en active Pending
- 2020-07-08 KR KR1020227004042A patent/KR20220032078A/ko unknown
- 2020-07-08 MX MX2022000251A patent/MX2022000251A/es unknown
- 2020-07-08 BR BR112022000144A patent/BR112022000144A2/pt unknown
-
2022
- 2022-01-04 CL CL2022000016A patent/CL2022000016A1/es unknown
- 2022-01-06 IL IL289673A patent/IL289673A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3145872A1 (en) | 2021-01-14 |
MX2022000251A (es) | 2022-02-21 |
EP3997104A1 (en) | 2022-05-18 |
AU2020309161A1 (en) | 2022-01-27 |
JP2022541752A (ja) | 2022-09-27 |
CN114341158A (zh) | 2022-04-12 |
BR112022000144A2 (pt) | 2022-02-22 |
IL289673A (en) | 2022-03-01 |
US20220315554A1 (en) | 2022-10-06 |
WO2021005131A1 (en) | 2021-01-14 |
KR20220032078A (ko) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000016A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo | |
CL2023001991A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo | |
PE20091753A1 (es) | Conjugados antagonistas peptidicos analogos a la bombesina | |
MX2015011243A (es) | Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. | |
PE20161153A1 (es) | Insulina de accion prolongada y uso de la misma | |
RU2012147267A (ru) | Эффективные аналоги компстатина | |
ES2585580T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
MX347200B (es) | Péptidos procoagulantes y sus derivados, y usos para estos. | |
UA103015C2 (ru) | Новые производные инсулина с чрезвычайно замедленным профилем время/действие | |
BR112022000122A2 (pt) | Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos | |
CO6150201A2 (es) | Anticuerpo humanizado contra beta amiloide | |
MX2014011459A (es) | Proteinas nutritivas cargadas y metodos. | |
NZ583435A (en) | A feeder cell-free culture medium and system | |
DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
AR114960A1 (es) | Proteína tolerante a herbicida, gen codificante y uso de la misma | |
RU2015146739A (ru) | Комплексы типа сахаридная цепочка-полипептид | |
NZ781143A (en) | Anti-vegf protein compositions and methods for producing the same | |
EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии | |
WO2012126118A8 (en) | Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy | |
TR201901259T4 (tr) | Karaciğere özgü tanı için hidrofobik modifiye peptidler. | |
RU2015130287A (ru) | Адаптация вируса гриппа н5 к человеку | |
ES2607490T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
RU2013145467A (ru) | Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 | |
CN104619717A (zh) | β-转角模拟肽环状化合物的合成 | |
MY151307A (en) | Peptides having antimicrobial activity |